Plain-English translation of NCT06096779 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , an immune-boosting medication, works safely and effectively for people with advanced liver cancer who also have severe liver cirrhosis. Some participants will receive alone, while others will receive it combined with , another medication that blocks blood vessel growth to tumors. This is an early-stage study (Phase II) enrolling about 30 people who have not received prior systemic cancer treatment.
Most people with advanced liver cancer and severe cirrhosis have very limited treatment options, and existing therapies don't work well enough for them. This trial aims to see if this medication can offer a new, safer treatment option for this vulnerable group.
You will visit the study center regularly to receive your assigned medication (either one or two drugs, depending on which group you are placed in) and have your blood tested and scans performed to monitor how you are responding. You will continue treatment until the medication stops helping, side effects become unacceptable, or your doctor determines you should stop. The study team will closely monitor your liver function and overall health throughout your participation.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States